[go: up one dir, main page]

SG11201908813QA - Anti-sirp alpha antibodies - Google Patents

Anti-sirp alpha antibodies

Info

Publication number
SG11201908813QA
SG11201908813QA SG11201908813QA SG11201908813QA SG 11201908813Q A SG11201908813Q A SG 11201908813QA SG 11201908813Q A SG11201908813Q A SG 11201908813QA SG 11201908813Q A SG11201908813Q A SG 11201908813QA
Authority
SG
Singapore
Prior art keywords
oss
international
kloosterstraat
pct
antibodies
Prior art date
Application number
Inventor
Eenennaam Hans Van
Elsas Andrea Van
Erik Voets
Paul Vink
David Lutje Hulsik
Original Assignee
Aduro Biotech Holdings Europe B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2018708A external-priority patent/NL2018708B1/en
Application filed by Aduro Biotech Holdings Europe B V filed Critical Aduro Biotech Holdings Europe B V
Publication of SG11201908813QA publication Critical patent/SG11201908813QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT oimiolo VIII °nolo VIII iflo X11 ois (10) International Publication Number WO 2018/190719 A2 (51) International Patent Classification: Not classified (21) International Application Number: PCT/NL2018/050234 (22) International Filing Date: 13 April 2018 (13.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2018708 13 April 2017 (13.04.2017) NL 2019166 03 July 2017 (03.07.2017) NL (71) Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V. [NL/NL]; Kloosterstraat 9 RX1101, 5349 AB Oss (NL). (72) Inventors: VAN EENENNAAM, Hans; c/o Klooster- straat 9 RX1101, 5349 AB Oss (NL). VAN ELSAS, An- drea; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL). VOETS, Erik; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL). VINK, Paul; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL). HULSIK, David Lutje; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL). (74) Agent: JANSEN, C.M.; V.O., Camegieplein 5, 2517 KJ Den Haag (NL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) 1-1 (54) Title: ANTI-SIRP ALPHA ANTIBODIES (57) : The present invention relates to anti-SIRPct antibodies, as well as use of these antibodies in the treatment of diseases C such as cancer and infectious disease.
SG11201908813Q 2017-04-13 2018-04-13 Anti-sirp alpha antibodies SG11201908813QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2018708A NL2018708B1 (en) 2017-04-13 2017-04-13 ANTI-SIRPα ANTIBODIES
NL2019166 2017-07-03
PCT/NL2018/050234 WO2018190719A2 (en) 2017-04-13 2018-04-13 Anti-sirp alpha antibodies

Publications (1)

Publication Number Publication Date
SG11201908813QA true SG11201908813QA (en) 2019-10-30

Family

ID=63793537

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908813Q SG11201908813QA (en) 2017-04-13 2018-04-13 Anti-sirp alpha antibodies

Country Status (12)

Country Link
US (3) US10851164B2 (en)
EP (1) EP3609922A2 (en)
JP (3) JP7160833B2 (en)
KR (2) KR20240135066A (en)
CN (2) CN118267470A (en)
AU (2) AU2018252546B2 (en)
CA (1) CA3058134A1 (en)
IL (2) IL315837A (en)
MX (2) MX2019012233A (en)
SG (1) SG11201908813QA (en)
TW (2) TW202430219A (en)
WO (1) WO2018190719A2 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66062B1 (en) * 2016-04-14 2024-11-29 Ose Immunotherapeutics New anti-sirpa antibodies and their therapeutic applications
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
KR20240039236A (en) 2016-12-09 2024-03-26 알렉터 엘엘씨 Anti-sirp-alpha antibodies and methods of use thereof
SG11201908813QA (en) * 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
EP4144372A3 (en) 2018-03-21 2023-06-14 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
MX2020011828A (en) 2018-05-25 2021-02-09 Alector Llc SIGNAL REGULATORY ALPHA PROTEIN ANTIBODIES (SIRPA) AND METHODS OF USE THEREOF.
IL317587A (en) 2018-07-10 2025-02-01 Univ Kobe Nat Univ Corp Anti-sirp? antibody
AU2019349651B2 (en) 2018-09-27 2023-12-07 Celgene Corporation SIRP alpha binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CN113573728A (en) 2018-11-14 2021-10-29 安驰肿瘤公司 Therapeutic SIRP alpha antibodies
US12180295B2 (en) * 2018-11-15 2024-12-31 Byondis B.V. Humanized anti-SIRPα antibodies
WO2020127369A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
JP7675012B2 (en) 2018-12-21 2025-05-12 オーエスイー・イミュノセラピューティクス Bifunctional anti-PD-1/SIRPA molecule
CN113614109A (en) 2018-12-21 2021-11-05 Ose免疫疗法公司 Bifunctional anti-PD-1/IL-7 molecules
KR102371173B1 (en) 2018-12-21 2022-03-04 오제 이뮈노테라프틱스 Humanized Anti-Human-PD-1 Antibody
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2020180811A1 (en) * 2019-03-04 2020-09-10 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
WO2020257196A1 (en) * 2019-06-17 2020-12-24 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating infections by blocking pathogen mimics of cd47
US20220305081A1 (en) * 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
CN114615989A (en) * 2019-07-17 2022-06-10 里兰斯坦福初级大学理事会 Integrin-targeted knottin-FC fusions and anti-CD 47 antibodies for treatment of cancer
CA3147420A1 (en) 2019-07-26 2021-02-04 Abl Bio Inc. Anti-egfr/anti-4-1bb bispecific antibody and use thereof
CN118178645A (en) 2019-10-18 2024-06-14 四十七公司 Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia
KR20220091576A (en) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 Anti-CD47 and Anti-CD20 Based Treatment of Hematological Cancers
BR112022008817A2 (en) 2019-11-27 2022-07-26 Alx Oncology Inc COMBINED THERAPIES FOR CANCER TREATMENT
HRP20241518T1 (en) 2019-12-24 2025-01-03 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CN114040925B (en) * 2019-12-24 2023-04-28 礼新医药科技(上海)有限公司 anti-SIRP alpha monoclonal antibody and application thereof
PH12022552122A1 (en) 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
US20230340112A1 (en) * 2020-02-28 2023-10-26 Apexigen, Inc. Anti-sirpa antibodies and methods of use
CA3177961A1 (en) * 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
JP2023528341A (en) 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド Combination therapy to treat cancers with hypomethylating agents
CN112138163B (en) * 2020-08-25 2022-08-23 江苏大学 Application of PPARG activator and SIRP alpha antibody in preparation of tumor immune drugs
CN116133694A (en) * 2020-10-14 2023-05-16 江苏恒瑞医药股份有限公司 Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and medical application thereof
WO2022098642A1 (en) 2020-11-03 2022-05-12 Rdiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
IL302812A (en) 2020-11-11 2023-07-01 Daiichi Sankyo Co Ltd Combinations of an antibody-drug conjugate with anti-sirp alpha antibody
CN115368455A (en) * 2020-11-30 2022-11-22 启愈生物技术(上海)有限公司 Specific antibody of targeted human SIRP alpha protein and application thereof
JP2023552375A (en) 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド Multimers for reducing interference of drugs that bind to CD47 in serological assays
CN112574310B (en) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 anti-SIRP alpha antibodies and uses thereof
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
CA3216908A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN117355539A (en) * 2021-05-28 2024-01-05 百奥泰生物制药股份有限公司 Anti-SIRPα antibodies and their applications
US11572412B2 (en) 2021-06-04 2023-02-07 Boehringer Ingelheim International Gmbh Anti-SIRP-alpha antibodies
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4362977A1 (en) 2021-06-29 2024-05-08 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
BR112024002199A2 (en) 2021-08-05 2024-04-30 Immunos Therapeutics Ag COMBINATION DRUGS COMPRISING HLA FUSION PROTEINS
EP4389767A1 (en) * 2021-08-17 2024-06-26 Hangzhou Jiuyuan Gene Engineering Co., Ltd Monoclonal antibody targeting sirp? and use thereof
CN113956363B (en) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 Recombinant fusion protein targeting CD47 and CD24 and preparation and application thereof
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (en) 2021-10-29 2024-06-20 Gilead Sciences Inc CD73 COMPOUNDS
CN118488948A (en) 2021-12-22 2024-08-13 吉利德科学公司 IKAROS zinc finger family degraders and their uses
JP2024546851A (en) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
JP2025509610A (en) 2022-03-17 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (en) 2022-04-05 2025-03-11 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
CN119032108A (en) * 2022-04-20 2024-11-26 博奥信生物技术（南京）有限公司 Antibodies targeting SIRPα and uses thereof
JP2025513258A (en) 2022-04-21 2025-04-24 ギリアード サイエンシーズ， インコーポレイテッド KRA G12D modulating compounds
JPWO2023219072A1 (en) 2022-05-10 2023-11-16
CN117164719A (en) * 2022-05-28 2023-12-05 启愈生物技术(上海)有限公司 Bispecific antibodies targeting SIRPα and PD-L1 or antigen-binding fragments thereof and their applications
WO2023235754A1 (en) 2022-06-01 2023-12-07 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
KR20250122479A (en) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 PRMT5 inhibitors and uses thereof
US12129499B2 (en) 2023-01-06 2024-10-29 Seismic Therapeutic, Inc. Protease variants and uses thereof
EP4662230A1 (en) 2023-02-08 2025-12-17 ImmunOs Therapeutics AG Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa
CN120882725A (en) 2023-04-11 2025-10-31 吉利德科学公司 KRAS-regulated compounds
CN121079300A (en) 2023-04-21 2025-12-05 吉利德科学公司 PRMT5 inhibitors and their uses
WO2024227083A2 (en) * 2023-04-28 2024-10-31 Abilita Bio, Inc. Anti-ccr8 antibodies, conjugates, and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117624336A (en) * 2023-10-31 2024-03-01 武汉爱博泰克生物科技有限公司 An expression, purification and detection method of active recombinant hSIRPA protein
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0604181A1 (en) 1992-12-21 1994-06-29 Eli Lilly And Company Antitumor compositions and method of treatment
WO1994019357A1 (en) 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
AU6909194A (en) 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
EP0670314A4 (en) 1993-09-22 1996-04-10 Kyowa Hakko Kogyo Kk FARNESYL-TRANSFERASE INHIBITOR.
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Pharmaceutical compositions for inhibition of g-protein function and for treatment of proliferative diseases containing tricyclic compounds some such compounds and process for preparing part of them
NZ275646A (en) 1993-10-15 1998-02-26 Schering Corp Tricyclic sulphonamide derivatives and medicaments
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
HUT76066A (en) 1993-10-15 1997-06-30 Schering Corp Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases, pharmaceutical compositions containing them and process for producing them
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JPH09504295A (en) 1993-10-25 1997-04-28 パーク・デイビス・アンド・カンパニー Substituted tetra- and pentapeptide inhibitors of protein: farnesyl transferase
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE69417012T2 (en) 1993-11-04 1999-10-07 Abbott Laboratories, Abbott Park CYCLOBUTAN DERIVATIVES AS INHIBITORS OF SQUALEN SYNTHETASE AND PROTEIN-FARNESYLTRANSFERASE
EP0730605A1 (en) 1993-11-05 1996-09-11 Warner-Lambert Company Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
WO1995024612A1 (en) 1994-03-07 1995-09-14 International Business Machines Corporation Fast process and device for interpolating intermediate values from periodic phase-shifted signals and for detecting rotary body defects
FI963597L (en) 1994-03-15 1996-11-14 Eisai Co Ltd Isoprenyltransferase inhibitors
RU95104898A (en) 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Imedazole containing inhibitors of ferneside proteintansferase, and method of treatment diseases related therewith
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US5563255A (en) 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
WO1995034535A1 (en) 1994-06-10 1995-12-21 Rhone-Poulenc Rorer S.A. Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
WO1996005529A1 (en) 1994-08-09 1996-02-22 Micron Optics, Inc. Temperature compensated fiber fabry-perot filters
ATE188464T1 (en) 1994-08-11 2000-01-15 Banyu Pharma Co Ltd SUBSTITUTED AMIDE DERIVATIVES
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
AU3192495A (en) 1994-08-12 1996-03-07 Banyu Pharmaceutical Co., Ltd. N,n-disubstituted amic acid derivative
DE4429506B4 (en) 1994-08-19 2007-09-13 Degussa Gmbh Process for the extraction of natural carotenoid dyes
DE4429653C2 (en) 1994-08-20 1997-04-03 Anton Dr More Converter and method for refining molten metals, in particular from pig iron to steel
EP0740853B1 (en) 1994-11-22 1999-01-13 Koninklijke Philips Electronics N.V. Semiconductor device with a carrier body on which a substrate with a semiconductor element is fastened by means of a glue layer and on which a pattern of conductor tracks is fastened
CA2204144A1 (en) 1994-12-09 1996-06-13 Francis J. Tinney Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
BR9606896A (en) 1995-01-09 1997-10-21 Magla Int Ltd Water resistant image printing on latex surfaces
AU4915796A (en) 1995-01-12 1996-07-31 University Of Pittsburgh Inhibitors of prenyl transferases
FR2729390A1 (en) 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2730491B1 (en) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2730492B1 (en) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
IL117805A0 (en) 1995-04-07 1996-08-04 Schering Corp Carbonyl piperazinyl and piperidinyl compounds
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions comprising them
US5891872A (en) 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
IL118101A0 (en) 1995-05-03 1996-09-12 Abbott Lab Inhibitors of farnesyltransferase
AU6034296A (en) 1995-06-16 1997-01-15 Warner-Lambert Company Tricyclic inhibitors of protein farnesyltransferase
FR2736641B1 (en) 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AT402617B (en) 1995-07-11 1997-07-25 Datacon Schweitzer & Zeindl Gm SYSTEM FOR AUTOMATED, HERMETIC SYSTEM FOR AUTOMATED, HERMETIC LOCKING OF HOUSINGS LOCKING OF HOUSINGS
FR2736638B1 (en) 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CH690163A5 (en) 1995-07-28 2000-05-31 Symphar Sa Derivatives substituted gem-diphosphonates useful as anti-cancer.
WO1997017070A1 (en) 1995-11-06 1997-05-15 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
PT1186606E (en) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf DERIVATIVES OF THE EPOTILONE ITS PREPARATION AND UTILIZATION
AU704139B2 (en) 1995-11-22 1999-04-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU711142B2 (en) 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
WO1997023478A1 (en) 1995-12-22 1997-07-03 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1997026246A1 (en) 1996-01-16 1997-07-24 Warner-Lambert Company Substituted histidine inhibitors of protein farnesyltransferase
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CZ376498A3 (en) 1996-05-22 1999-02-17 Warner-Lambert Company Protein farnesyl transferase inhibitors
JP2000514456A (en) 1996-07-15 2000-10-31 ブリストル―マイヤーズ・スクイブ・カンパニー Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP1003374A4 (en) 1996-12-30 2000-05-31 Merck & Co Inc FARNESYL-PROTEIN TRANSFERASE INHIBITORS
EP0951285A1 (en) 1996-12-30 1999-10-27 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE319745T1 (en) 1997-05-21 2006-03-15 Biovation Ltd METHOD FOR PRODUCING NON-IMMUNOGENIC PROTEINS
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
JP2002531466A (en) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド Humanized antibodies to gamma interferon
EP1151002A4 (en) 1999-01-29 2002-05-02 Imclone Systems Inc Antibodies specific to kdr and uses thereof
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp Use of anti-vegf antibody to enhance radiation in cancer therapy
ES2601882T5 (en) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedure to monitor the activity of an immunofunctional molecule
EP1048299A1 (en) 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
WO2001040307A1 (en) * 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antibodies against signal regulator proteins
JP2004501642A (en) 2000-06-28 2004-01-22 グライコフィ，　インコーポレイテッド Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1379251B1 (en) 2001-04-10 2008-07-09 Merck & Co., Inc. Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
WO2002083064A2 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
WO2002083675A2 (en) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
JP2005511581A (en) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Mitotic kinesin inhibitor
ATE424388T1 (en) 2001-12-06 2009-03-15 Merck & Co Inc MITOTIC KINESIN INHIBITORS
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
DE60232994D1 (en) 2001-12-06 2009-08-27 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
ATE447577T1 (en) 2001-12-06 2009-11-15 Merck & Co Inc MITOTIC KINESIN INHIBITORS
EP1463733B1 (en) 2001-12-06 2007-09-05 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003105855A1 (en) 2002-01-11 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE448207T1 (en) 2002-03-08 2009-11-15 Merck & Co Inc MITOTIC KINESIN INHIBITORS
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
WO2003084473A2 (en) 2002-04-08 2003-10-16 Merck & Co., Inc. Method of treating cancer
EP1494676B1 (en) 2002-04-08 2013-05-08 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of akt activity
JP4451136B2 (en) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Akt activity inhibitor
JP4394959B2 (en) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Inhibitor of AKT activity
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
CA2483627A1 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US20050203110A1 (en) 2002-05-23 2005-09-15 Coleman Paul J. Mitotic kinesin inhibitors
JP4463679B2 (en) 2002-06-14 2010-05-19 メルク エンド カムパニー インコーポレーテッド Mitotic kinesin inhibitor
CA2500848A1 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
EP1558586B1 (en) 2002-10-30 2011-03-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2004053059A2 (en) 2002-12-06 2004-06-24 Pharmacia Corporation Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
JP2006516140A (en) 2002-12-20 2006-06-22 メルク　エンド　カムパニー　インコーポレーテッド Mitotic kinesin inhibitor
CA2508956A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE446752T1 (en) 2003-04-24 2009-11-15 Merck & Co Inc ACT ACTIVITY INHIBITOR
CN100422158C (en) 2003-04-24 2008-10-01 麦克公司 Akt activity inhibitor
EP1622616B1 (en) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN1809351A (en) 2003-04-24 2006-07-26 麦克公司 Inhibitors of Akt activity
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2004112699A2 (en) 2003-06-12 2004-12-29 Merck & Co., Inc. Mitotic kinesin inhibitors
US7296030B2 (en) 2003-07-17 2007-11-13 At&T Corp. Method and apparatus for windowing in entropy encoding
JP2007500508A (en) * 2003-07-29 2007-01-18 モルフォテック、インク． Methods for producing recombinant antibodies with enhanced antibody and effector functions
KR100536215B1 (en) 2003-08-05 2005-12-12 삼성에스디아이 주식회사 Plasma display panel
CA2533435A1 (en) 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
US7638549B2 (en) 2003-08-15 2009-12-29 Merck & Co. Inc. Mitotic kinesin inhibitors
DK1664026T3 (en) 2003-08-15 2009-05-04 Merck & Co Inc Inhibitors of mitotic kinesin
PE20050730A1 (en) 2003-08-15 2005-09-20 Merck & Co Inc DERIVATIVES OF 2,5-DIHYDROPYRROL 2,2-DISUSTITUTED AS INHIBITORS OF MYTHOTIC KINESINS
JP2007502773A (en) 2003-08-15 2007-02-15 メルク　エンド　カムパニー　インコーポレーテッド Mitotic kinesin inhibitor
US7294640B2 (en) 2004-02-06 2007-11-13 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4887284B2 (en) 2004-03-15 2012-02-29 デイビッド・ケイ・アール・カラオリス Methods for inhibiting the growth of cancer cells or increasing apoptosis of cancer cells
DE602005026509D1 (en) 2004-04-09 2011-04-07 Merck Sharp & Dohme HEMMER OF ACT ACTIVITY
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
ATE476993T1 (en) 2004-06-07 2010-08-15 Univ Ramot METHOD FOR PASSIVE IMMUNIZATION AGAINST A DISEASE CHARACTERIZED BY AMYLOID AGGREGATION OR DISEASE WITH A REDUCED RISK OF NEUR INFLAMMATION
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
DK3056515T4 (en) 2008-01-15 2025-10-20 Univ Leland Stanford Junior METHOD FOR MANIPULATING PHAGOCYTOSIS MEDIATED BY CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CN102239182B (en) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Antibody to MUC1*
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
PH12013500974A1 (en) * 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
KR20150095668A (en) 2012-12-13 2015-08-21 아두로 바이오테크, 인코포레이티드 Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014173886A1 (en) * 2013-04-22 2014-10-30 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
JP2016524593A (en) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター Compositions and methods for altering second messenger signaling
JP2016518140A (en) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cyclic dinucleotide derivatization of type I interferon
US9724408B2 (en) 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
EP3116544A4 (en) 2014-03-11 2017-08-23 The Board of Trustees of the Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
EP3131581B1 (en) * 2014-04-18 2020-09-23 The Research Foundation of the State University of New York Humanized anti-tf-antigen antibodies
MX2016015928A (en) 2014-06-04 2017-03-20 Glaxosmithkline Ip Dev Ltd Cyclic di-nucleotides as modulators of sting.
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6692826B2 (en) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． Compositions and methods for activation of "interferon gene stimulator" dependent signaling
WO2017011444A1 (en) 2015-07-13 2017-01-19 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating b cell cancers
UA123701C2 (en) 2015-08-13 2021-05-19 Мерк Шарп І Доум Корп. Cyclic di-nucleotide compounds as sting agonists
EP3402801B1 (en) 2016-01-11 2025-08-06 Innate Tumor Immunity, Inc. Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CR20200045A (en) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
CN109071664B (en) 2016-04-14 2023-02-21 Ose免疫疗法 Novel anti-SIRPa antibodies and therapeutic uses thereof
WO2018008470A1 (en) 2016-07-05 2018-01-11 国立大学法人神戸大学 Antitumor agent
WO2018009648A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN106200187B (en) 2016-07-07 2019-04-09 京东方科技集团股份有限公司 Dimmable glass, controllable shading device, method and vehicle
EP3484504A4 (en) 2016-07-15 2020-07-29 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CA3031034A1 (en) 2016-08-03 2018-02-08 The Board Of Trustees Of The Leland Stanford Junior University Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
UA125223C2 (en) 2016-10-04 2022-02-02 Мерк Шарп І Доум Корп. BENZO [b] THIOPHENE COMPOUNDS AS STING AGONISTS
KR20240039236A (en) 2016-12-09 2024-03-26 알렉터 엘엘씨 Anti-sirp-alpha antibodies and methods of use thereof
SG11201908813QA (en) 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
MX2019013749A (en) * 2017-05-16 2020-01-15 Synthon Biopharmaceuticals Bv ANTI-SIRPa ANTIBODIES.
KR102670957B1 (en) 2017-07-26 2024-05-31 포티 세븐, 인코포레이티드 Anti-SIRP-alpha antibodies and related methods
IL317587A (en) * 2018-07-10 2025-02-01 Univ Kobe Nat Univ Corp Anti-sirp? antibody
US12180295B2 (en) * 2018-11-15 2024-12-31 Byondis B.V. Humanized anti-SIRPα antibodies
CN111635458A (en) * 2020-03-20 2020-09-08 上海健信生物医药科技有限公司 Antibody or antigen-binding fragment thereof targeting Sirpα and preparation and application thereof
WO2022110922A1 (en) * 2020-11-30 2022-06-02 启愈生物技术(上海)有限公司 ANTI-SIRPα ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
US11572412B2 (en) * 2021-06-04 2023-02-07 Boehringer Ingelheim International Gmbh Anti-SIRP-alpha antibodies

Also Published As

Publication number Publication date
WO2018190719A3 (en) 2019-10-31
JP7745527B2 (en) 2025-09-29
US20180312587A1 (en) 2018-11-01
AU2018252546A1 (en) 2019-10-10
IL269405B2 (en) 2025-04-01
AU2025204402A1 (en) 2025-07-03
JP2022191386A (en) 2022-12-27
EP3609922A2 (en) 2020-02-19
IL269405B1 (en) 2024-12-01
IL269405A (en) 2019-11-28
US10851164B2 (en) 2020-12-01
JP2025041767A (en) 2025-03-26
CN118267470A (en) 2024-07-02
TW202430219A (en) 2024-08-01
KR102702926B1 (en) 2024-09-06
JP2020516300A (en) 2020-06-11
WO2018190719A2 (en) 2018-10-18
JP7160833B2 (en) 2022-10-25
TWI841526B (en) 2024-05-11
TW201841943A (en) 2018-12-01
US20220135671A1 (en) 2022-05-05
IL315837A (en) 2024-11-01
KR20190140454A (en) 2019-12-19
MX2019012233A (en) 2020-01-14
AU2018252546B2 (en) 2025-03-13
CN110650976B (en) 2024-04-19
MX2023014569A (en) 2024-02-08
CN110650976A (en) 2020-01-03
KR20240135066A (en) 2024-09-10
US20220135677A1 (en) 2022-05-05
CA3058134A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201909011PA (en) Niraparib compositions
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201810801QA (en) Brain delivery protein
SG11201809341PA (en) Mobile robot
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201805001UA (en) Method of treating influenza a
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201909837YA (en) Methods for treating lung disorders